Search 

The everbeat platform is being offered by Grektek, whose mission is to help dramatically improve cardiac care. We created everbeat to improve our ability to take care of ourselves, especially as we get older, and with a strong focus on heart health. Most existing solutions related to cardiac care are unattractive and cumbersome, and brand the patient as weak or sickly. At Grektek, we designed everbeat to be elegant and simple, allowing patients to take better care of themselves with dignity and comfort. We also believe that patients will enjoy the everbeat solution, which means they will use it consistently for a long time – and sustained use of a cardiac monitoring platform is essential to getting healthy.

Angine Biotech (Angine) is a international business development solution provider company dedicated in the pharma, biotech and medical device fields for the global business partnership building. We are working with our overseas' business partner to introduce the clinical and market unmet projects/products to China by leveraging the local expertise and resources. 

With the professional international BD team, the expert consultant group as well as the valuable data room for Chinese markets in the biotech and health care field, Angine is committed to provide the tailor-made solutions for the overseas’ partners who would like to explore the access to the Chinese markets. The solutions are including but not limited to the Chinese market landscape investigation, the regulatory affairs support, the reimbursement policy study, the ideal incubator and strategic biz partner recommendation, as well as the capital and talent services when the project is confirmed to settle in the referred incubator or campus.

Angine would like work with you as a strategic partner to co-develop the Chinese healthcare market, to make your ideas or IP become the products by inputting the expertise from both sides.

You can write an email to leoluo@anginebio.com for your ideas and proposals for the Chinese markets. Let our team give you a solution.

Mira Life Science Ventures was established to change the paradigm for investment, incubation and development of new disruptive and game-changing technologies in the life sciences. Mira LSV will invest in medical devices, therapeutics, diagnostics, enabling technologies and digital healthcare. Mira LSV will focus its efforts in areas of significant unmet medical needs such as cancer, neurological diseases, infectious disease, autoimmune disease, inflammatory diseases, personalized medicine, cardiovascular disease and renal diseases.

In order to change the venture investment paradigm, Mira LSV was formed to break out of the traditional venture model and move to a more flexible, nimble and shareholder-centric model to accelerate development of these break-through products and technologies and bring them to patients. Mira LSV’s highly flexible business structure, broad and diverse access to deal-flow and highly experienced management team will ensure we have a significant positive impact on our healthcare system.

Myriad Genetics is a technology-enabled molecular diagnostics company, with worldwide presence. Our genetic tests play in Oncology, Women's Health (e.g., prenatal), and Mental Health areas. 

Strategy, Management and fundraising for genomic companies. Invest and help raise capital through private and public placements in the US, as well as guide company executives on Operational execution in the molecular diagnostics industry.

Personalis, Inc. headquartered in Menlo Park California, USA, Was established in 2011 as a Stanford University spin-out by a team of internationally-renown Next Generation Sequencing (NGS) thought leaders to provide advanced genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and cancer immunotherapies by providing more comprehensive molecular data bout each patient’s cancer and immune response. The Personalis ImmunoID NeXT Platform TM is designed to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers with information on all of the approximately 20,000 human genes, together with the immune system, from a single tissue sample The Personalis Clinical Laboratory in Menlo Park, Califonria is GxP aligned as well as CLIA’88-certified and CAP-accredited.

On 10 June 2020 Personalis, Inc announced a partnership with Berry Genomics with plans to expand operations in PRC with a wholly-owned subsidiary in Shanghai. Berry will provide sequencing services and local support to Personalis operation in Shanghai. Personalis, Inc was granted approval for a business license for Shanghai Personalis Biotechnology Co, LTD on 15 October 2020. The expansion to China includes buildout of a laboratory operation for local customers to use its ImmunoID Next Platform, a commercial team to support local customers and general and administrative functions.